BioCentury | Jul 1, 2013
Company News

Ibex management update

Ibex Technologies Inc. (TSX-V:IBT), Montreal, Quebec Business: Cancer, Autoimmune, Diagnostic Hired: Richard Collin as director of finance WIR Staff autoimmune cancer Diagnostic...
BioCentury | Apr 15, 2013
Clinical News

Ibex preclinical data

...in San Diego. Neutralase is in clinical tests for heparin reversal after coronary bypass surgery. Ibex Technologies Inc....
BioCentury | Apr 15, 2013
Clinical News

Ibex preclinical data

...factors. The data were presented at the American Society for Cell Biology meeting in Washington. Ibex Technologies Inc....
BioCentury | Nov 6, 2006
Strategy

A shelf full of antihistamines

...to develop and commercialize oral bilastine to treat or prevent rhinitis from Faes Farma S.A. (IBEX:FAE...
BioCentury | Nov 6, 2006
Company News

Inspire, Faes deal

...testing to treat cystic fibrosis (CF). Inspire Pharmaceuticals Inc. (ISPH), Durham, N.C. Faes Farma S.A. (IBEX...
BioCentury | Nov 2, 2006
Company News

Inspire licenses Faes' bilastine

...Faes (IBEX:FAE) granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize...
BioCentury | Sep 29, 2003
Product Development

Assumptions didn't pan out

...In 1998, Ibex Technologies Inc. discontinued a Phase III trial of its Neutralase heparinase in cardiopulmonary bypass surgery...
...due to excess bleeding in the Neutralase group. Despite those problems, BioMarin Pharmaceutical Inc. bought Ibex...
...the company last week terminated the Neutralase program, and now will have to monetize the Ibex...
BioCentury | Sep 29, 2003
Clinical News

Neutralase: Phase IIIa

...the Phase IIIa trial would not demonstrate favorable safety and efficacy. BMRN acquired Neutralase from Ibex Technologies Inc....
BioCentury | Sep 22, 2003
Top Story

BioMarin terminates Neutralase

...heparin in primary coronary artery bypass graft ( CABG ) surgery. BMRN acquired Neutralase from Ibex...
BioCentury | Jul 21, 2003
Company News

Ibex deal

...make three annual payments of C$400,000 in order to retain rights to HDM's arthritis biomarkers. Ibex Technologies Inc....
Items per page:
1 - 10 of 53
BioCentury | Jul 1, 2013
Company News

Ibex management update

Ibex Technologies Inc. (TSX-V:IBT), Montreal, Quebec Business: Cancer, Autoimmune, Diagnostic Hired: Richard Collin as director of finance WIR Staff autoimmune cancer Diagnostic...
BioCentury | Apr 15, 2013
Clinical News

Ibex preclinical data

...in San Diego. Neutralase is in clinical tests for heparin reversal after coronary bypass surgery. Ibex Technologies Inc....
BioCentury | Apr 15, 2013
Clinical News

Ibex preclinical data

...factors. The data were presented at the American Society for Cell Biology meeting in Washington. Ibex Technologies Inc....
BioCentury | Nov 6, 2006
Strategy

A shelf full of antihistamines

...to develop and commercialize oral bilastine to treat or prevent rhinitis from Faes Farma S.A. (IBEX:FAE...
BioCentury | Nov 6, 2006
Company News

Inspire, Faes deal

...testing to treat cystic fibrosis (CF). Inspire Pharmaceuticals Inc. (ISPH), Durham, N.C. Faes Farma S.A. (IBEX...
BioCentury | Nov 2, 2006
Company News

Inspire licenses Faes' bilastine

...Faes (IBEX:FAE) granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize...
BioCentury | Sep 29, 2003
Product Development

Assumptions didn't pan out

...In 1998, Ibex Technologies Inc. discontinued a Phase III trial of its Neutralase heparinase in cardiopulmonary bypass surgery...
...due to excess bleeding in the Neutralase group. Despite those problems, BioMarin Pharmaceutical Inc. bought Ibex...
...the company last week terminated the Neutralase program, and now will have to monetize the Ibex...
BioCentury | Sep 29, 2003
Clinical News

Neutralase: Phase IIIa

...the Phase IIIa trial would not demonstrate favorable safety and efficacy. BMRN acquired Neutralase from Ibex Technologies Inc....
BioCentury | Sep 22, 2003
Top Story

BioMarin terminates Neutralase

...heparin in primary coronary artery bypass graft ( CABG ) surgery. BMRN acquired Neutralase from Ibex...
BioCentury | Jul 21, 2003
Company News

Ibex deal

...make three annual payments of C$400,000 in order to retain rights to HDM's arthritis biomarkers. Ibex Technologies Inc....
Items per page:
1 - 10 of 53